Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05618600

Enrollment

917

Registered

2022-11-16

Start date

2022-08-04

Completion date

2024-06-10

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Paxlovid, Rebound, COVID-19

Brief summary

A prospective monitoring study for those individuals treated with Paxlovid

Detailed description

The purpose of this study is to understand the epidemiology and pathophysiology of Paxlovid rebound in patients with acute Covid-19 infection who have been prescribed the Paxlovid per standard of care. The study will be a collaborative effort between Scripps and eMed, digitally recruiting 800 participants who have tested positive for Covid-19 and have agreed to be prescribed Paxlovid on the eMed platform. The vision of the study is to understand Paxlovid rebound and ultimately inform management of acute Covid-19 infection.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age \> 18 * Covid positive * Qualified for Paxlovid prescription (treatment decision already made prior to enrollment)

Exclusion criteria

* Non-english speaking * Resides outside of the United States

Design outcomes

Primary

Measure	Time frame	Description
Paxlovid Rebound	16 day period	Incidence of paxlovid rebound defined as test positivity after a documented negative rapid antigen test post 5 day course of Paxlovid

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJay Pandit, MD

Scripps Research Institute

Outcome results